Evidence map›Paper›PMID 37404450›Full record

ArticleHealth science reports2023

Clinical characteristics of COVID-19 patients infected by the Omicron variants in Macao, China: A cross-sectional study.

Hou Hon Cheong, Fong I Sio, Chi Chung Chan, Seong In Neng, Ip Pio Sam, Teng Cheang, Weng Ieong Tou, Hong San Lei, Tan Fong Cheong, Edmundo Patricio Lopes Lao and 3 more

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Hou Hon CheongHealth Bureau Macao SAR China.ORCID 0000-0002-8027-2510
Fong I SioHealth Bureau Macao SAR China.
Chi Chung ChanHealth Bureau Macao SAR China.
Seong In NengHealth Bureau Macao SAR China.
Ip Pio SamHealth Bureau Macao SAR China.
Teng CheangHealth Bureau Macao SAR China.
Weng Ieong TouHealth Bureau Macao SAR China.
Hong San LeiHealth Bureau Macao SAR China.
Tan Fong CheongHealth Bureau Macao SAR China.
Edmundo Patricio Lopes LaoHealth Bureau Macao SAR China.
Tak Hong CheongHealth Bureau Macao SAR China.
Cheong U KuokHealth Bureau Macao SAR China.
Iek Long LoHealth Bureau Macao SAR China.
Food and Health Bureau · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The evolving mutants of SARS-CoV-2 have made the COVID-19 pandemic sustained for over 3 years. In 2022, BA.4 and BA.5 were the Omicron variants dominating the spread globally. Although COVID-19 was no longer a Public Health Emergency of International Concern (PHEIC) as announced by WHO, the SARS-CoV-2 variants remain a challenge to global healthcare under the circumstances of withdrawal and loosening of personal protective behavior in the post-quarantine era. This study aims to acknowledge the clinical characteristics caused by Omicron BA.4/BA.5 in COVID-19 naive people and analyze possible factors affecting disease severities. Methods: In this retrospective study, we report and analyze the clinical features of 1820 COVID-19 patients infected with the BA.4/BA.5 Omicron variants of SARS-CoV-2 during a local outbreak that occurred in Macao SAR, China, from June to July 2022. Results: A total of 83.5% of patients were symptomatic eventually. The most common symptoms were fever, cough, and sore throat. Hypertension, dyslipidemia, and diabetes mellitus were the leading comorbidities. There were significantly more elderly patients ( Conclusion: Our data are consistent with a milder disease caused by BA.4/5 Omicron variants in the general population, while patients with old age and comorbidities have developed severe to critical diseases. Complete vaccination series and booster doses are effective strategies to reinforce protection against severe diseases and avoid mortality.

Indexed as

infectious diseasespublic healthrespiratory medicinevaccines

Identifiers

PMID37404450
PMCPMC10316466
OpenAlexW4382938967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.